The following conclusions are presented:
- 5-year survival in 3316 participants with advanced HIV disease pre-ART was excellent (CDM 87%, LCM 90%)
- Loss to follow-up was very low
- Routine laboratory monitoring for toxicity did not impact adverse events or substitutions in first line
- 12-weekly CD4 monitoring had no impact on disease progression during
the first 2 years on ART
- after 2 years, a small but significant impact on clinical disease progression favouring LCM appeared to be driven by later switch to second-line ART in CDM
- there may be a role for targeted, as opposed to routine, CD4 monitoring from the second year on ART
Presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 19-22 July 2009, 28 pp.
The Development of Anti-Retroviral Therapy in Africa (DART) trial. Comparison of routine vs clinically driven laboratory monitoring in HIV-infected African adults over 5 years on ART: Final results of the DART trial.